{Reference Type}: Case Reports
{Title}: Controversial Flow Cytometry Monitoring of a Relapse Case of Pediatric T Cell Acute Lymphoblastic Leukemia: A Case Report.
{Author}: Popa DC;Şerbănică A;Obrisca R;Şerbănică I;Radu L;Jercan C;Marcu A;Bica A;Asan M;Petran M;Dragomir M;Jardan C;Ţică V;Gheorghe A;Stoian I;Coriu D;Coliţă A;Coliţă A;Popa DC;Şerbănică A;Obrisca R;Şerbănică I;Radu L;Jercan C;Marcu A;Bica A;Asan M;Petran M;Dragomir M;Jardan C;Ţică V;Gheorghe A;Stoian I;Coriu D;Coliţă A;Coliţă A;
{Journal}: Front Med (Lausanne)
{Volume}: 9
{Issue}: 0
{Year}: 2022
{Factor}: 5.058
{DOI}: 10.3389/fmed.2022.858809
{Abstract}: Acute lymphoblastic leukemia (ALL) is the most frequent childhood cancer, with 80-85% represented by B cell ALL and only 15% by T cell ALL. T Cell ALL (T-ALL) carries a more reserved prognosis compared to B Cell ALL (B-ALL) with regard to response to treatment, risk of relapse, and overall survival. Progress made in current monitoring protocols such as via flow cytometry immunophenotyping (FCM) and by PCR-based amplification of antigen-receptor genes led to improved management of patients with ALL and superior rates of survival. Nevertheless, challenges remain in some clinical cases. This manuscript describes a unique case of T-ALL and raises awareness of such clinical challenges. The article presents an overview of the flow cytometry immunophenotyping at diagnosis and during treatment of a pediatric patient with T-ALL from Fundeni Clinical Institute. In this case, in spite of various therapeutic measures such as first-line chemotherapy for high risk group, salvage chemotherapy (FLAG), conditioning regimen (FLU-BU-TT-ATG), and stem cell transplant, a chemoresistance clone continued to be present.